立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

farmaceutica biochem international s.r.l. - loperamido hidrochloridas - kietosios kapsulės - 2 mg - loperamide

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - amoksicilinas/klavulano rūgštis - plėvele dengtos tabletės - 500 mg/125 mg; 875 mg/125 mg - amoxicillin and beta-lactamase inhibitor

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - amoksicilinas/klavulano rūgštis - milteliai injekciniam ar infuziniam tirpalui - 1000 mg/200 mg - amoxicillin and beta-lactamase inhibitor

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - amoksicilinas/klavulano rūgštis - disperguojamosios tabletės - 500 mg/125 mg; 875 mg/125 mg - amoxicillin and beta-lactamase inhibitor

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - amoksicilinas/klavulano rūgštis - milteliai geriamajai suspensijai - 400 mg/57 mg/5 ml - amoxicillin and beta-lactamase inhibitor

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

mip pharma gmbh - amoksicilinas - tabletės - 500 mg; 1000 mg - amoxicillin

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - amoksicilinas/klavulano rūgštis - plėvele dengtos tabletės - 875 mg/125 mg; 500 mg/125 mg - amoxicillin and beta-lactamase inhibitor

欧盟 - 立陶宛文 - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

欧盟 - 立陶宛文 - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artritas, reumatas - imunosupresantai - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

立陶宛 - 立陶宛文 - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - amoksicilinas - disperguojamosios tabletės - 750 mg - amoxicillin